[1]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145-148.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Journal of Medical Information,2023,36(02):145-148.[doi:10.3969/j.issn.1006-1959.2023.02.031]
点击复制

紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年02期
页码:
145-148
栏目:
药物与临床
出版日期:
2023-01-15

文章信息/Info

Title:
The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes
文章编号:
1006-1959（2023）02-0145-04
作者:
石少庆; 宋丽丽
（佳木斯市肿瘤结核医院肿瘤五科，黑龙江 佳木斯 154007）
Author(s):
SHI Shao-qing; SONG Li-li
(The Fifth Department of Oncology,Jiamusi Tumor and Tuberculosis Hospital,Jiamusi 154007,Heilongjiang,China)
关键词:
紫杉醇; 卡铂; 三阴性乳腺癌; 新辅助化疗; 病理分级
Keywords:
Paclitaxel; Carboplatin; Triple negative breast cancer; Neoadjuvant chemotherapy; Pathological grading
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2023.02.031
文献标志码:
A
摘要:
目的 观察紫杉醇联合卡铂辅助治疗三阴性乳腺癌临床效果及对患者病理变化的影响。方法 选取2020年6月-2021年11月在我院诊治的64例三阴性乳腺癌患者为研究对象，采用随机数字表法分为对照组和观察组，各32例。对照组采用紫杉醇联合环磷酰胺、表柔比星胺治疗，观察组采用紫杉醇联合卡铂治疗，比较两组临床治疗效果、生存时间、T淋巴细胞因子水平、病理组织分级情况以及不良反应发生情况。结果 观察组治疗总有效率为90.63%，高于对照组的75.00%（P＜0.05）；观察组生存时间大于对照组（P＜0.05）；两组化疗后CD3+、CD4+均高于化疗前，CD8+均低于化疗前，且观察组CD3+、CD4+均高于对照组，CD8+低于对照组（P＜0.05）；观察组化疗后病理组织Ⅰ、Ⅱ级率均低于对照组，Ⅳ、Ⅴ级均高于对照组（P＜0.05），Ⅲ级与对照组比较，差异无统计学意义（P＞0.05）；观察组不良反应发生率为9.38%，低于对照组的18.75%（P＜0.05）。结论 采用紫杉醇联合卡铂方案对三阴性乳腺癌进行新辅助化疗治疗，可提高治疗总有效率，改善病理分级，延长患者生存时间，提高机体免疫力，且不良反应少，是一种有效、可行的新辅助化疗方案。
Abstract:
Objective To observe the clinical effect of paclitaxel combined with carboplatin in adjuvant treatment of triple negative breast cancer and its influence on pathological changes.Methods A total of 64 patients with triple negative breast cancer who were diagnosed and treated in our hospital from June 2020 to November 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 32 cases in each group. The control group was treated with paclitaxel combined with cyclophosphamide and epirubicin, and the observation group was treated with paclitaxel combined with carboplatin. The clinical efficacy, survival time, T lymphocyte factor level, pathological tissue grading and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 90.63%, which was higher than 75.00% in the control group (P<0.05). The survival time of the observation group was longer than that of the control group (P<0.05). After chemotherapy, CD3+ and CD4+ in the two groups were higher than those before chemotherapy, CD8+ was lower than that before chemotherapy, and CD3+ and CD4+ in the observation group were higher than those in the control group, CD8+ was lower than that in the control group (P<0.05). After chemotherapy, the rates of pathological tissue grades Ⅰ and Ⅱ in the observation group were lower than those in the control group, and grades Ⅳ and Ⅴ were higher than those in the control group (P<0.05), but there was no significant difference in grade Ⅲ between the observation group and the control group (P>0.05). The incidence of adverse reactions in the observation group was 9.38%, which was lower than 18.75% in the control group (P<0.05).Conclusion Neoadjuvant chemotherapy with paclitaxel combined with carboplatin for triple-negative breast cancer can improve the total effective rate of treatment, improve the pathological grade, prolong the survival time of patients, improve the immunity of the body, and have fewer adverse reactions. It is an effective and feasible neoadjuvant chemotherapy regimen.

参考文献/References:

[1]黄庆炜.紫杉醇脂质体联合表柔比星对三阴性乳腺癌新辅助化疗的临床疗效和预后相关因素的研究分析[J].中国处方药,2019,17(6):82-83.[2]张岭,王珏,陈锐,等.紫杉醇与白蛋白结合型紫杉醇在HER2阴性乳腺癌新辅助化疗中的疗效研究[J].南京医科大学学报,2018,38(6):807-811.[3]冯轲昕,王翔,王昕.增殖细胞核抗原Ki-67及其在新辅助化疗前后的变化与乳腺癌预后的关系[J].癌症进展,2019,17(13):1494-1497.[4]杨海松,毛大华,张世泳,等.紫杉醇联合表阿霉素新辅助化疗治疗三阴性乳腺癌的临床疗效评价及其对Ki-67、p53、P-gp和GST-π的影响[J].现代生物医学进展,2017,17(22):4281-4284.[5]姚和瑞,游凯云,汪颖,等.Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率[J].循证医学,2017,17(3):140-145,134.[6]陈燕玉,周敏,王旭禛,等.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的疗效[J].江苏医药,2017,43(6):401-403.[7]Tutt A,Tovey H,Cheang MCU,et al.Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial[J].Nat Med,2018,24(5):628-637.[8]胡利敏,陈述政,周毅,等.密集AC序贯密集紫杉醇新辅助化疗对三阴性乳腺癌的近期疗效[J].肿瘤学杂志,2018,24(3):199-202.[9]边志杰,杨彬.紫杉醇脂质体联合表柔比星新辅助化疗三阴性乳腺癌临床疗效分析[J].中国现代普通外科进展,2016,19(2):104-108.[10]李莉,王友群,孙蔚莉,等.含铂方案治疗晚期乳腺癌临床研究[J].中华肿瘤防治杂志,2016,23(10):657-662.[11]沙如拉,李文新.TC对比ET治疗晚期三阴性乳腺癌的临床观察[J].内蒙古医学杂志,2017,49(2):143-146.[12]Shaitelman SF,Stauder MC,Allen P,et al.Impact of statin use on outcomes in triple negative breast cancer[J].J Cancer,2017,8(11): 2026-2032[13]杨金喆.三阴性乳腺癌卡铂联合紫杉醇新辅助化疗疗效分析[J].临床军医杂志,2016,44(9):970-972.[14]Shi Y, Jin J, Ji W,et al.Therapeutic landscape in mutational triple negative breast cancer[J].Mol Cancer,2018,17(1):99.[15]马建萍,张宝亮,赵成鹏.表柔比星联合紫杉醇治疗三阴性乳腺癌的临床观察[J].实用癌症杂志,2017,15(3):341-342.[16]杨辉,江皓.新辅助TAC化疗对早期乳腺癌患者疗效、细胞免疫功能和Ki-67的影响[J].中华全科医学,2017,15(4):555-557,671.[17]谢宁,田璨,刘莉萍,等.含卡培他滨联合化疗方案序贯卡培他滨维持治疗转移性乳腺癌患者的疗效观察[J].中国肿瘤临床与康复,2017,24(1):1-5.[18]陈燕玉,周敏,王旭禛,等.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的疗效[J].江苏医药,2017,43(6):401-403.[19]周强,刘颂莲,胡建兵.紫杉醇联合卡铂在晚期三阴性乳腺癌一线治疗的疗效观察[J].现代诊断与治疗,2016,26(8):1447-1448.

相似文献/References:

[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,31(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
　PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Journal of Medical Information,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
[2]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Journal of Medical Information,2020,33(02):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[3]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
　GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Journal of Medical Information,2020,33(02):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Journal of Medical Information,2019,32(02):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]王小毛,黄 晶,石 峰.金龙胶囊对耐紫杉醇及卡铂卵巢癌H08910细胞的逆转及增敏作用[J].医学信息,2020,33(04):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
　WANG Xiao-mao,HUANG Jing,SHI Feng.Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells[J].Journal of Medical Information,2020,33(02):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
[6]吴仁瑞,汪 琛,刘 超.紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性[J].医学信息,2022,35(20):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
　WU Ren-rui,WANG Chen,LIU Chao.Short-term Efficacy and Safety of Concurrent Chemoradiotherapy with Paclitaxel and Carboplatin in Stage Ⅲ Gastroesophageal Junction Cancer[J].Journal of Medical Information,2022,35(02):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]

更新日期/Last Update: 1900-01-01